LncRNA expression profiling in exosomes derived from synovial fluid of patients with rheumatoid arthritis
Copyright © 2024 Elsevier B.V. All rights reserved..
OBJECTIVE: To identify the long non-coding RNA (lncRNA) expression profiling in exosomes derived from synovial fluid of rheumatoid arthritis (RA) patients, and carry out bioinformatics analysis on target genes of differentially expressed lncRNAs.
METHODS: Exosomes were isolated from synovial fluid via ultracentrifugation. RNAs were extracted from exosomes by using HiPure Liquid RNA/miRNA kits, followed by lncRNA sequencing. Differentially expressed lncRNAs in RA were screened, and bioinformatics analysis of their target genes was carried out. qRT-PCR was used to verify the lncRNA expression levels.
RESULTS: Compared with osteoarthritis (OA), 347 lncRNAs were found differentially expressed in RA. Compared with gout, 805 lncRNAs were found differentially expressed in RA. Compared with both OA and gout, 85 lncRNAs were found specially expressed in RA (65 were upregulated (including ENST00000433825.1)). Functional analysis of target genes of the specially expressed lncRNAs revealed significant enrichment of "autophagy" and "mTOR signaling pathway". The qRT-PCR results indicated that ENST00000433825.1 was highly expressed in RA, compared with both OA and gout (P < 0.05), which matched the lncRNA sequencing results. Correlation analysis showed that the level of ENST00000433825.1 in RA patients was significantly and positively correlated with the level of C-reactive protein (CRP) (P < 0.001).
CONCLUSIONS: The lncRNA expression profiling in exosomes derived from synovial fluid of RA was significantly different from OA and gout. ENST00000433825.1 was highly and uniquely expressed in RA and significantly and positively correlated with CRP, which might provide a diagnostic and therapeutic biomarker for RA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
International immunopharmacology - 130(2024) vom: 30. März, Seite 111735 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Shanmiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2024.111735 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369026020 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369026020 | ||
| 003 | DE-627 | ||
| 005 | 20240325234959.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2024.111735 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1346.xml |
| 035 | |a (DE-627)NLM369026020 | ||
| 035 | |a (NLM)38412675 | ||
| 035 | |a (PII)S1567-5769(24)00253-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Shanmiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a LncRNA expression profiling in exosomes derived from synovial fluid of patients with rheumatoid arthritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 25.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVE: To identify the long non-coding RNA (lncRNA) expression profiling in exosomes derived from synovial fluid of rheumatoid arthritis (RA) patients, and carry out bioinformatics analysis on target genes of differentially expressed lncRNAs | ||
| 520 | |a METHODS: Exosomes were isolated from synovial fluid via ultracentrifugation. RNAs were extracted from exosomes by using HiPure Liquid RNA/miRNA kits, followed by lncRNA sequencing. Differentially expressed lncRNAs in RA were screened, and bioinformatics analysis of their target genes was carried out. qRT-PCR was used to verify the lncRNA expression levels | ||
| 520 | |a RESULTS: Compared with osteoarthritis (OA), 347 lncRNAs were found differentially expressed in RA. Compared with gout, 805 lncRNAs were found differentially expressed in RA. Compared with both OA and gout, 85 lncRNAs were found specially expressed in RA (65 were upregulated (including ENST00000433825.1)). Functional analysis of target genes of the specially expressed lncRNAs revealed significant enrichment of "autophagy" and "mTOR signaling pathway". The qRT-PCR results indicated that ENST00000433825.1 was highly expressed in RA, compared with both OA and gout (P < 0.05), which matched the lncRNA sequencing results. Correlation analysis showed that the level of ENST00000433825.1 in RA patients was significantly and positively correlated with the level of C-reactive protein (CRP) (P < 0.001) | ||
| 520 | |a CONCLUSIONS: The lncRNA expression profiling in exosomes derived from synovial fluid of RA was significantly different from OA and gout. ENST00000433825.1 was highly and uniquely expressed in RA and significantly and positively correlated with CRP, which might provide a diagnostic and therapeutic biomarker for RA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Exosomes | |
| 650 | 4 | |a Long non-coding RNA | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 700 | 1 | |a Liang, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Qidang |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Zhuyi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xingjian |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Paifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Shaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yalian |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Tianwang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Zhengqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yukai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 130(2024) vom: 30. März, Seite 111735 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g day:30 |g month:03 |g pages:111735 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111735 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |b 30 |c 03 |h 111735 | ||